ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO897

Mycophenolate Mofetil (MMF) and Corticosteroids in Crescentic IgA Nephropathy (IgAN)

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Vargas-Brochero, Maria Jose, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Machado, Miriam, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Valencia-Morales, Nancy Daniela, Hospital Clinico San Carlos, Madrid, Comunidad de Madrid, Spain
  • Zand, Ladan, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Radhakrishnan, Yeshwanter, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Soler, Maria Jose, Hospital Universitari Vall d'Hebron, Barcelona, Catalunya, Spain
  • Fervenza, Fernando C., Mayo Clinic Minnesota, Rochester, Minnesota, United States

There is no gold standard for the treatment of crescentic IgAN.


Biopsy-proven crescentic IgAN patients treated with MMF plus corticosteroids 2000-2022(Figure1).Renal outcomes analyzed: hematuria, proteinuria,estimated glomerular filtration rate(eGFR),and end-stage kidney disease(ESKD) after one year.


A total of 22 patients ,72.7% male,86.4% white, age 38.9±15.3 years. Follow-up 3.9±2 years. Baseline serum creatinine(sCr)2.0±0.78mg/dl,and 100% had hematuria. Kidney biopsy showed(MEST, M1 [90.9%], E1 [59.1%] ,S1[86.4%] ,T0[59.1%], T1[27.3%], T2[13.6%], C1[72.7%], C2[27.3%]).95.4% no previous immunosuppression,77.3% Intravenous methylprednisolone,and 100% received oral corticosteroids, time biopsy to MFF 19 [IQR3.5-69.5] days.
At one-year, kidney survival 100%, hematuria disappeared in 68.4%, eGFR(CKD-EPI) increased from 35.6[IQR24.7-71.5] to 51.3[IQR36.4-87]ml/min/1.73m2(p=0.003), proteinuria g/24h decreased from 1.8[IQR 1.2-4.0] to 0.55 [IQR0.2-1.3](p=0.003).The renal survival with IFTA≥40% was 40% vs. 88.2%with IFTA<40%. Persistent hematuria(PH) had a renal survival of 50% vs. 92.3% with no PH.Most common adverse event was infection(n=6), with temporary treatment discontinuation.22.7% developed ESKD.


MMF plus corticosteroids is associated with 100% kidney survival at one year and 77.3% at the end of follow-up. Advanced interstitial fibrosis and PH seem to be associated with worse prognosis in crescentic IgAN.